Our research group is investigating the signalling and biological functions of GDNF family ligands and endoplasmic reticulum located CDNF/MANF neurotrophic factor families, both within and outside of the nervous system. We are also interested in the therapeutic potential of these proteins in various diseases, so we are testing their efficacy in animal models of Parkinson's disease, amyotrophic lateral sclerosis, stroke and diabetes mellitus. One of the highlights of our research has been, in 2020, the successful completion of phase I-II clinical trials of CDNF protein in Parkinson's disease patients by the Finnish company Herantis Pharma Plc.
Neurotrophic Factors and Regeneration
Mart Saarma Research Group
A portrait of Professor Mart Saarma was unveiled in Viikki
The portrait of Professor Mart Saarma was painted by Estonian artist Margus Meinart.
Diabetes: Unconventional neurotrophic factor MANF may regenerate insulin-producing cells in the pancreas
MANF has therapeutic potential for the treatment of Type 1 and Type 2 diabetes.
ERC Starting Grants to four researchers at the University of Helsinki
Four researchers from the University of Helsinki have received the European Research Council’s (ERC) Starting Grant.
The Chemical Industry Federation of Finland’s Innovation Award to the team of the Institute of Biotechnology and Herantis Pharma
CDNF protein treatment for Parkinsons’ disease developed by Herantis Pharma and the team of the Institute of Biotechnology was presented with...
US department of defense grant to support ALS research at University of Helsinki
With the help of the two-year Therapeutic Idea Award from the US Department of Defense professor Saarma and Dr. Voutilainen aim to generate more...
Our research group is investigating the signalling and biological functions of GDNF family ligands and endoplasmic reticulum located CDNF/...
This is a list of the latest publications from Professor Mart Saarma. Links to the lists of publications from individual group members...